Non-invasive Diastolic Stress Testing in a Large Observational Cohort Study: Insights from the Dallas Heart Study
Abstract Body (Do not enter title and authors here): Introduction: Despite its increasing prevalence and significant morbidity/mortality in the aging population, heart failure with preserved ejection fraction (HFpEF) remains challenging to diagnose as its symptoms may occur only during exercise. In smaller studies, non-invasive diastolic stress testing has been validated in diagnosing exercise-induced increase in diastolic filling pressures. However, its feasibility in a large real-world population has not been tested. Aims: The Dallas Heart Study is a multiethnic, probability-based, population cohort study of Dallas County residents with deliberate oversampling of black individuals. The study sample consisted of 712 participants with LVEF≥50% and free of prevalent HF who attended the 3rd phase of the Dallas Heart Study (2021-2024) and underwent diastolic stress echocardiography. Methods: Participants underwent comprehensive resting echo followed by a submaximal stress echo protocol which includes pedaling on a supine echocardiography bicycle at a fixed workload of 30W. Per 2016 stress echocardiography recommendations by the American Society of Echocardiography (ASE), a definitive abnormal test was defined when the following criteria are met: septal E/e′ ratio>15, average E/e′>14, peak TR velocity>2.8 m/s with exercise, and either septal e′<7 or lateral e′<10 cm/s at rest. Results: Mean age was 59±11 years, and 56% were women (Table 1). 48% of the participants were Black, 32% White, and 18% Hispanic. Mean BMI was 31±7 kg/m2, 23% had diabetes, and 59% had hypertension. Between rest and stress (Table 2), there were statistically significant increases in LVEF, LV GLS, e’, mean E/e’, peak TR velocity, LA volume index, and LA reservoir strain. At rest, 5% of the participants had abnormal E/e’ (defined as >14), while at stress 8% did. To identify predictors of abnormal E/e’, backwards (P <0.001) multivariable stepwise regression modeling was performed on baseline demographics and resting echo variables and found lateral E/e’ as the only independent predictor (OR 1.86, 95% CI 1.40-2.46). Notably, 2% of the participants were found to have a definite abnormal diastolic stress test per ASE recommendation. Conclusion: We have demonstrated the feasibility of performing non-invasive diastolic stress testing on a large contemporary real-world cohort. With rapidly emerging HFpEF therapies, more widespread adoption of an effective and safe diagnostic tool for HFpEF is needed to warrant adequate and individualized treatment.
Chandra, Alvin
( UT Southwestern Medical Center
, Dallas
, Texas
, United States
)
Yang, Yimin
( Brigham and Women's Hospital
, Woodland
, California
, United States
)
Zeleke, Yinun
( UT Southwestern Medical Center
, Dallas
, Texas
, United States
)
Pandey, Ambarish
( UT Southwestern Medical Center
, Dallas
, Texas
, United States
)
De Lemos, James
( UT SOUTHWESTERN MEDICAL CTR
, Dallas
, Texas
, United States
)
Berry, Jarett
( UT Tyler School of Medicine
, Tyler
, Texas
, United States
)
Shah, Amil
( UT Southwestern Medical Center
, Dallas
, Texas
, United States
)
Author Disclosures:
Alvin Chandra:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Novo Nordisk:Active (exists now)
| Yimin Yang:DO NOT have relevant financial relationships
| Yinun Zeleke:No Answer
| Ambarish Pandey:DO have relevant financial relationships
;
Consultant:Tricog:Active (exists now)
; Consultant:Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Anumana, Alleviant, Pfizer, Abbott, Axon Therapies, Kilele Health, Acorai, Kardigan, Novartis, Idorsia Pharma, and Science37:Active (exists now)
; Consultant:Rivus:Active (exists now)
; Consultant:iRhythm:Active (exists now)
; Researcher:SQ innovations:Active (exists now)
; Research Funding (PI or named investigator):SC Pharma:Active (exists now)
; Consultant:Astra Zeneca:Active (exists now)
; Research Funding (PI or named investigator):Ultromics:Active (exists now)
; Research Funding (PI or named investigator):Roche:Active (exists now)
; Consultant:Ultromics:Active (exists now)
; Consultant:Roche:Active (exists now)
; Consultant:Lilly:Active (exists now)
; Consultant:Bayer:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
| James de Lemos:DO have relevant financial relationships
;
Independent Contractor:Amgen, Inc.:Active (exists now)
; Independent Contractor:Verve:Active (exists now)
; Consultant:Siemen's:Past (completed)
; Independent Contractor:Jannsen:Active (exists now)
; Independent Contractor:Astra Zeneca:Past (completed)
; Independent Contractor:Merck:Active (exists now)
; Independent Contractor:Eli Lilli:Active (exists now)
; Independent Contractor:Varian:Active (exists now)
; Independent Contractor:Regerenon Pharmaceuticals:Active (exists now)
| Jarett Berry:DO have relevant financial relationships
;
Consultant:Cooper Institute:Past (completed)
| Amil Shah:DO NOT have relevant financial relationships